SYGNIS to present its innovative TruePrimeTM and SunScriptTM technologies for DNA amplification and sequencing at the American Society of Human Genetics Annual Meeting, ASHG 2015 in Baltimore
Madrid, Spain and Heidelberg, Germany, October 1, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it will present its proprietary portfolio of TruePrime™ and SunScript™ technologies for DNA amplification and sequencing at the Annual Meeting of the American Society of Human Genetics (ASHG), the ASHG 2015, which will be held from October 6 – 10, 2015 in Baltimore, Maryland. The ASHG today is the largest human genetics meeting worldwide with more than 6,500 attendees and over 200 exhibiting companies and represents a forum for presentations and discussions of cutting-edge science in all areas of human genetics.
Miguel Viribay Vice President Marketing and Sales at SYGNIS and Ángel J. Picher, Associate Director, Product Development will promote both the TruePrime™ and SunScript™ product lines at the Company’s own booth (number 2019). In addition, they will highlight and discuss the latest results of deep sequencing obtained with the TruePrime™ technology, that show superior genome coverage even from single cells when compared to traditional competing technologies, with key opinion leaders and potential future partners from the human genomics field.
“After rolling out our proprietary portfolio of products for DNA amplification and sequencing in Europe and building a strong network of distributors to cover the European markets, we are now moving forward in our product and commercialization strategy to more actively promote our products in the U.S., the main market for our innovative technologies,” commented Pilar de la Huerta, CEO and CFO of SYGNIS AG. “Presenting and hosting an own booth on a conference like the ASHG 2015, the most renowned event in the field of human genetics, is a huge opportunity for us to increase and improve the visibility of our products and technologies in U.S. markets.”
For more information on the ASHG 2015 Annual Meeting, please visit: http://www.ashg.org/2015meeting/.
TruePrime™ is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrime™ is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
About SunScript™ RT
SunScript™ RT is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScriptTM Reverse Transcriptase will be available in two versions: SunScript™ RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions for use e.g. in clinical diagnostics whereas SunScriptTM RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing (NGS) applications, in gene expression profiling and molecular diagnostics.
For further information please contact:
Pilar de la Huerta
Phone: +34 91 192 36 50
MC Services AG
Phone: +49 89 210228 30